Headwaters Capital Management, an investment management company, released its fourth-quarter 2024 investor letter. A copy of ...

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is ...

NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

JP Morgan has recently reduced TransMedics Group Inc (TMDX) stock to Neutral rating, as announced on December 17, 2024, according to Finviz. Earlier, on November 22, 2024, Needham had reduced the ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 12.34% on an annualized basis producing an average ...

NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ ...